Trial
NCT05316116
Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)
Early Phase ITERMINATEDEFFICACY/FUTILITYConfidence: HIGH
Sponsor
H. Lee Moffitt Cancer Center and Research Institute
Collaborators
EUSA Pharma, Inc.
Condition
Large Granular Lymphocyte Leukemia
Intervention
Siltuximab
Why stopped
lack of efficacy/futility
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-02-05